Business Context and Reporting Period
Company: REED's, INC. (NASDAQ: REED)
Filing Type: Form 8-K (Current Report)
Date of Report: October 22, 2019 (Event Date: October 23, 2019)
Context: The company announced the entry into a material definitive agreement for an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Shares Offered: 11,666,667 shares of common stock.
- Offering Price: $0.60 per share.
- Over-Allotment Option: Underwriter granted a 45-day option to purchase up to 1,750,000 additional shares.
- Expected Gross Proceeds: Approximately $7.0 million (or $8.05 million if the over-allotment option is fully exercised).
- Net Proceeds: Not specified; gross proceeds are before deducting underwriting discounts and offering expenses.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics as this is a transaction report, not a periodic financial statement.
Material Changes
The primary material change is the execution of an underwriting agreement with Roth Capital Partners, LLC. This represents a significant dilution event and a planned increase in the company's cash position upon closing.
Outlook, Risks, and Management Commentary
- Closing Date: Expected on or about October 25, 2019, subject to customary closing conditions.
- Regulatory Status: Shares are being sold pursuant to a shelf registration statement effective February 8, 2019. A preliminary prospectus supplement was filed on October 22, 2019.
- Indemnification: Reed's has agreed to indemnify the underwriters against certain liabilities under the Securities Act of 1933.
- Risks: The transaction is subject to satisfaction of customary closing conditions; failure to close would result in no proceeds.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after underwriting discounts.
- Confirm whether the underwriter exercises the 1,750,000 share over-allotment option.
- Review the final prospectus supplement for specific use of proceeds.
- Monitor the impact of the new share issuance on earnings per share (EPS) and ownership dilution.